| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, ErbB-2 | 13 | 2025 | 514 | 3.020 |
Why?
|
| Breast Neoplasms | 22 | 2025 | 2512 | 2.780 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2025 | 725 | 1.330 |
Why?
|
| Trastuzumab | 9 | 2025 | 134 | 1.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 1252 | 0.950 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2011 | 25 | 0.850 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 117 | 0.850 |
Why?
|
| NF-kappa B | 6 | 2011 | 459 | 0.830 |
Why?
|
| Curcumin | 3 | 2011 | 41 | 0.800 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 1892 | 0.760 |
Why?
|
| Azadirachta | 2 | 2011 | 2 | 0.740 |
Why?
|
| Signal Transduction | 16 | 2025 | 4537 | 0.740 |
Why?
|
| Plant Extracts | 2 | 2011 | 121 | 0.670 |
Why?
|
| Neuroblastoma | 4 | 2011 | 505 | 0.630 |
Why?
|
| Estrogen Receptor alpha | 4 | 2021 | 458 | 0.630 |
Why?
|
| Apoptosis | 6 | 2019 | 1803 | 0.610 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 341 | 0.570 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1696 | 0.550 |
Why?
|
| Gamma Rays | 3 | 2011 | 50 | 0.540 |
Why?
|
| Gene Fusion | 1 | 2016 | 55 | 0.510 |
Why?
|
| Biomarkers, Tumor | 7 | 2023 | 1491 | 0.500 |
Why?
|
| Radiation, Ionizing | 2 | 2011 | 41 | 0.450 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 3347 | 0.430 |
Why?
|
| Carrier Proteins | 2 | 2020 | 1024 | 0.430 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 320 | 0.400 |
Why?
|
| Rosaceae | 1 | 2011 | 1 | 0.380 |
Why?
|
| Molecular Targeted Therapy | 4 | 2025 | 361 | 0.380 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 540 | 0.380 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 54 | 0.370 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 74 | 0.360 |
Why?
|
| Quinazolines | 3 | 2023 | 174 | 0.360 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 100 | 0.360 |
Why?
|
| Mice, Nude | 5 | 2025 | 709 | 0.350 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 185 | 0.350 |
Why?
|
| Digestive System | 1 | 2010 | 61 | 0.350 |
Why?
|
| Genes, p53 | 1 | 2010 | 212 | 0.330 |
Why?
|
| Sarcoma, Ewing | 1 | 2010 | 109 | 0.320 |
Why?
|
| Receptors, Estrogen | 5 | 2021 | 795 | 0.320 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 1707 | 0.310 |
Why?
|
| Gene Amplification | 3 | 2019 | 230 | 0.310 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 210 | 0.300 |
Why?
|
| Genomics | 1 | 2016 | 1501 | 0.300 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 683 | 0.300 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 555 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 335 | 0.260 |
Why?
|
| Female | 22 | 2025 | 66722 | 0.260 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 691 | 0.240 |
Why?
|
| Protein Kinases | 2 | 2016 | 332 | 0.230 |
Why?
|
| Humans | 29 | 2025 | 125040 | 0.230 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 375 | 0.230 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2025 | 156 | 0.220 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2011 | 65 | 0.200 |
Why?
|
| Cell Survival | 4 | 2021 | 812 | 0.200 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 293 | 0.200 |
Why?
|
| Prognosis | 5 | 2021 | 4627 | 0.200 |
Why?
|
| Mice | 10 | 2025 | 17646 | 0.190 |
Why?
|
| Carcinogenesis | 1 | 2025 | 334 | 0.190 |
Why?
|
| Remission Induction | 2 | 2020 | 300 | 0.190 |
Why?
|
| Linear Energy Transfer | 2 | 2011 | 7 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 1214 | 0.190 |
Why?
|
| Plant Leaves | 2 | 2011 | 43 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 41 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 59 | 0.180 |
Why?
|
| Pyrimidinones | 1 | 2020 | 49 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 884 | 0.170 |
Why?
|
| Pyridones | 1 | 2020 | 118 | 0.160 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 19 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 212 | 0.160 |
Why?
|
| Pyridines | 1 | 2021 | 230 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 256 | 0.160 |
Why?
|
| Piperazines | 1 | 2021 | 239 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 116 | 0.160 |
Why?
|
| Cinnamates | 1 | 2018 | 15 | 0.160 |
Why?
|
| Brain | 1 | 2010 | 2999 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 100 | 0.150 |
Why?
|
| Animals | 10 | 2025 | 34246 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 410 | 0.140 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 3 | 0.140 |
Why?
|
| Indoles | 1 | 2018 | 189 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 763 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2019 | 319 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 573 | 0.130 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 1701 | 0.130 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 664 | 0.130 |
Why?
|
| Gene Expression | 1 | 2020 | 1561 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 1062 | 0.120 |
Why?
|
| Genomic Instability | 1 | 2016 | 229 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 488 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 113 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2018 | 2309 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2014 | 211 | 0.110 |
Why?
|
| Cell Separation | 1 | 2014 | 229 | 0.110 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 48 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1698 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5165 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 282 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 618 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2023 | 12384 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 2049 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2011 | 3 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 797 | 0.100 |
Why?
|
| Aniline Compounds | 1 | 2011 | 18 | 0.100 |
Why?
|
| Aminoquinolines | 1 | 2011 | 35 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 13 | 0.100 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2011 | 36 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 370 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2011 | 41 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1274 | 0.090 |
Why?
|
| Time Factors | 2 | 2011 | 6327 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 882 | 0.090 |
Why?
|
| Cell Movement | 1 | 2014 | 846 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 553 | 0.090 |
Why?
|
| Infrared Rays | 1 | 2010 | 23 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 71 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2011 | 281 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1758 | 0.080 |
Why?
|
| Fruit | 1 | 2011 | 220 | 0.080 |
Why?
|
| Telomerase | 1 | 2011 | 160 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 173 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 657 | 0.080 |
Why?
|
| Transfection | 1 | 2011 | 1069 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 487 | 0.080 |
Why?
|
| Phenotype | 2 | 2016 | 4260 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2020 | 363 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1290 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2011 | 2821 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 222 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1583 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1239 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 666 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2021 | 1633 | 0.060 |
Why?
|
| Base Sequence | 1 | 2010 | 3103 | 0.060 |
Why?
|
| DNA | 1 | 2011 | 1608 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3157 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1462 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 835 | 0.060 |
Why?
|
| Laminin | 1 | 2025 | 70 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 512 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 1286 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 1025 | 0.050 |
Why?
|
| Mutation | 2 | 2017 | 5846 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4408 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2016 | 867 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 89 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 89 | 0.040 |
Why?
|
| Dasatinib | 1 | 2020 | 41 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2020 | 91 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 74 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 69 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 359 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 214 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 313 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2009 | 135 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 166 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 361 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 173 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 6 | 0.030 |
Why?
|
| Estradiol | 1 | 2018 | 532 | 0.030 |
Why?
|
| Estrogens | 1 | 2018 | 504 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1504 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 236 | 0.030 |
Why?
|
| Middle Aged | 3 | 2020 | 26925 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 152 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 618 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1016 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 513 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2887 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 61 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 19862 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 241 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 303 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4397 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 1274 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1629 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 9 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 48 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 29625 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6596 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 245 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 670 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 1331 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 359 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 9042 | 0.020 |
Why?
|